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Summary
BACKGROUND—Equine type 1 polysaccharide storage myopathy (PSSM1) is associated with a 
missense mutation (R309H) in the glycogen synthase (GYS1) gene, enhanced glycogen synthase 
(GS) activity and excessive glycogen and amylopectate inclusions in muscle.
METHODS—Equine muscle biochemical and recombinant enzyme kinetic assays in vitro and 
homology modelling in silico, were used to investigate the hypothesis that higher GS activity in 
affected horse muscle is caused by higher GS expression, dysregulation, or constitutive activation 
via a conformational change.
RESULTS—PSSM1-affected horse muscle had significantly higher glycogen content than control 
horse muscle despite no difference in GS expression. GS activity was significantly higher in 
muscle from homozygous mutants than from heterozygote and control horses, in the absence and 
presence of the allosteric regulator, glucose 6 phosphate (G6P). Muscle from homozygous mutant 
horses also had significantly increased GS phosphorylation at sites 2+2a and significantly higher 
AMPKα1 (an upstream kinase) expression than controls, likely reflecting a physiological attempt 
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to reduce GS enzyme activity. Recombinant mutant GS was highly active with a considerably 
lower Km for UDP-glucose, in the presence and absence of G6P, when compared to wild type GS, 
and despite its phosphorylation.
CONCLUSIONS—Elevated activity of the mutant enzyme is associated with ineffective 
regulation via phosphorylation rendering it constitutively active. Modelling suggested that the 
mutation disrupts a salt bridge that normally stabilises the basal state, shifting the equilibrium to 
the enzyme's active state.
GENERAL SIGNIFICANCE—This study explains the gain of function pathogenesis in this 
highly prevalent polyglucosan myopathy.
Graphical abstract
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Introduction
The ability to store glucose as the branched-chain polymer glycogen is shared by organisms 
as evolutionarily diverse as bacteria and mammals: it enables organisms to deal with 
temporary starvation by maintaining energy provision through glycogen catabolism, and, in 
times of plenty, to store this energy macromolecule substrate in a form that has minimal 
effect on cellular osmotic pressure [1]. In mammals, glycogen is normally stored in muscle 
and other tissues following the action of 2 key enzymes: glycogen synthase (GS) and 
glycogen branching enzyme (GBE). GS catalyses the polymerisation of glucose from a 
UDP-glucose (UDPG) substrate via α1-4 glycosidic bonds and GBE is responsible for 
generating α1-6 bonds, every 4-10 residues [2]. There are 2 GS isoforms: one, encoded by 
the GYS1 gene and predominantly expressed in muscle but also in other tissues and the 
other encoded by the GYS2 gene and expressed only in liver. Both GS isoforms are 
regulated by protein kinase-catalysed phosphorylation and allosteric modulation by 
glucose-6-phosphate (G6P) [3].
There are more than 14 glycogen storage diseases in humans and animals [4-7], several of 
which are characterised by excessive muscle glycogen or polyglucosan and caused by 
enzymatic defects in glycogenesis or glycogenolysis. In 2008, a missense, autosomal 
dominant mutation (R309H) in GYS1 was identified in Quarter Horses with polysaccharide 
storage myopathy (PSSM1) [8], a disease characterised by intermittent exertional 
rhabdomyolysis episodes and excessive muscle glycogen and amylopectate accumulation [9, 
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10] but with an absence of cardiac signs [11]. The R309H mutation is associated with 
increased GS activity in muscle from affected horses [8]. The identical mutation has now 
been reported in many horse breeds worldwide [12-15] suggesting dissemination from a 
single founder and in certain breeds, positive selection [16] perhaps due to the increased 
muscle glycogen storage in affected animals [8]. Since the ratio of GS: GBE activity is 
important in the formation of glycogen with a normal structure [17], filamentous alpha 
crystalline polysaccharide that forms in PSSM1-affected muscle likely develops because of 
an increased GS: GBE activity ratio [18] as seen in transgenic mice with constitutively 
active muscle GS [19]. The mechanism by which the equine R309H mutation results in 
increased GS activity is unknown; potential mechanisms include elevated GS expression, 
reduced degradation or dysregulation of enzyme activity. However, since the R309H 
mutation occurs in a highly conserved region of all GS enzymes and a mutation of an 
adjacent amino acid in yeast GS (equivalent to amino acid G310 in mammalian GS) also 
results in increased enzyme activity [20], it is possible that mutations in this region cause 
constitutive enzyme activation.
Covalent regulation of GS is dependent on 9 separate phosphorylation sites that are modified 
by various upstream kinases; of these, phosphorylation at sites 2 (serine residue S7), 2a 
(S10), 3a (S641) and 3b (S645) decrease the enzyme activity more than the remaining 5 sites 
[21-23]. Furthermore, phosphorylation of certain sites enables sequential phosphorylation of 
others so that they can be functionally grouped for investigative purposes [24]. Two of the 
key upstream kinases responsible for marked inhibition of GS are glycogen synthase kinase 
3β (GSK3β) (which phosphorylates sites 3a, 3b, 3c, and 3d) and AMP-activated protein 
kinase (AMPK), which phosphorylates GS at site 2. Other kinases, namely Casein Kinase 2 
and Protein kinase A, are associated with phosphorylation at sites 1a, 1b and 5 which have 
little effect on GS activity [24]. The phosphorylation of GS has a significant effect on G6P 
affinity; indeed, regulation by G6P is associated with a feed-forward mechanism that causes 
further enzyme activation by dephosphorylation [25]. Although the R309H residue is distant 
in the primary sequence from any of the known phosphorylation sites, the mutation could 
result in an inappropriate response to phosphorylation as is seen in a yeast GS variant [20].
Although the crystal structure has not been published for any mammalian GS, the structures 
for a bacterial GT5 synthase (Agrobacterium tumefaciens) [2] and, more recently, for a yeast 
synthase (Saccharomyces cerevisiae; Gsy2p) [26] and a Caenorhabditis elegans synthase 
[27] have been solved. Yeast GS is a homo-tetrameric protein in both its basal and active 
states and eukaryotic GT3 synthases likely have a similar tetrameric arrangement due to 
their high sequence identity [26]. Since the amino acid sequence surrounding the PSSM1 
R309H GYS1 mutation is highly conserved amongst species [8] it is possible that this site 
might have an important (but as yet unknown) functional role [2, 28]. It is not however 
thought to be involved in substrate binding [2, 29] or catalytic activity [2, 20, 30].
The binding of the G6P ligand to GS is complex [26]. The structural basis for G6P allosteric 
activation has been revealed from analysis of high-resolution crystal structures of the 
homologous synthase enzyme, Gsy2p from Saccharomyces cerevisiae: GS has a binding 
pocket for the phosphate side chain of G6P that comprises 5 amino acid residues that are 
conserved across the GT3 family glycosyltransferases [26]. G6P binding results in a major 
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conformational change involving translation and rotation toward the tetramer interface of the 
enzyme to generate the active form [26]. Co-crystallisation of Gsy2p with maltodextrin 
polymers (used as analogues to detect glycogen binding sites) shows that there are at least 4 
maltodextrin sites for this substrate in the enzyme's active form [31]. Only binding sites 1 
and 2 are exposed in the basal form of GS [31]: these sites might be important for enabling 
the enzyme to remain bound to glycogen even when GS activity is reduced by 
phosphorylation [32].
Improved understanding of the mechanism by which the R309H mutation in equine GYS1 
leads to the mutant enzyme's increased activity might help further elucidate the functional 
significance of an incompletely characterised domain of this fundamentally important 
mammalian enzyme. Furthermore, it could prompt investigation of specific treatments for 
this common equine myopathy or for other related glycogenoses in humans [33]. In this 
work, we investigate the enzyme's regulation in silico via computational modelling and 
through biochemical analysis in vitro of whole muscle extracts and via recombinant 
expressed enzyme kinetics. We hypothesised that higher GS activity in affected horse 
muscles is caused by (1) higher GS expression; (2) altered GS regulation by allosteric 
effectors or by covalent phosphorylation; or (3) constitutive activation via a conformational 
structural change.
Materials and Methods
Muscle sample collection
Muscle samples were collected by open biopsy under local anaesthesia from the 
semimembranosus muscle of 12 homozygous normal (RR), 13 heterozygote (HR) and 4 
homozygous mutant (HH) Belgian and Percheron draught horses according to ethical 
approval from the Institutional Animal Care and Use Committee (University of Auburn). All 
horses were maintained at the university research facility and were managed at pasture and 
fed identically. Horses were selected on the basis of age- and sex-matching of individuals of 
differing genotype, following genotyping of the entire herd of horses using an established 
restriction fragment polymorphism assay [8]. Samples were snap-frozen in liquid nitrogen, 
shipped on dry ice and stored at −80°C until use.
Glycogen content measurement
Total glycogen was measured in 50 mg wet weight muscle biopsy samples using a 
colorimetric assay [34] (RR=7, RH=8, HH=4).
GS activity
GS activity was measured using radiolabelled UDP-glucose [35] in the presence of low 
(0.02 mM), medium (0.17 mM) and high (8 mM) G6P concentrations. Calculation of the 
fractional velocity of the enzyme, %FV (100 × [activity (0.17 mM G6P)/activity (8 mM 
G6P)]) enables investigation of the regulation of GS by G6P. Calculation of G6P-
independent activity, % I-form (100 × [activity (0.02 mM G6P)/activity (8 mM G6P)]) 
enables investigation of GS regulation by phosphorylation [35-37].
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Briefly, 20 μg of homogenised muscle (RR n=12, RH n=13, HH n=4) was placed into wells 
of a 96 well plate (Nunc) in duplicate and 40 μl of each of 3 different glucose concentration 
(final glucose concentrations: 0.02 mM, 0.17 mM or 8 mM) reagents were added. Samples 
were incubated with the glucose reagent (containing differing G6P concentrations, 25 mM 
Tris-HCl, 5 mM ethylene-diamine-tetra-acetic acid (EDTA), 10 mg/ml glycogen, 50 mM 
NaF, 2.5 mM unlabelled UDPG and 50 μl/ml UDPG (14C)) for 25 minutes at 37°C and then 
50 μl of the mixture was added to wells of Unifilter 96 well plates (Whatman) containing 
200 μl 66% ice-cold ethanol in ddH20 water. The plates were then incubated at −20°C for 2h 
and subsequently washed in ice-cold 66% ethanol 5 times. Plates were then dried for 15 
minutes at 37°C and 75 μl of Microscint 40 scintillation fluid (Perkin Elmer) was added to 
each well before counting using a top-count NXT scintillation counter (Perkin Elmer).
Muscle homogenisation
For measurement of total GS expression, skeletal muscle homogenates were prepared from 
50 mg of snap frozen biopsy tissue dissected free of any visible fat or connective tissue and 
crushed using a pestle and mortar cooled using dry-ice. The powder was then dissolved in 1 
ml of protein extraction buffer containing phosphatase inhibitors, heated at 100°C for 5 
minutes and subsequently centrifuged (16000g for 5 minutes at 4°C). The supernatant was 
removed and its protein concentration measured using the Pierce BCA protein assay.
A modified extraction was performed on skeletal muscle homogenates for measurement of 
phosphorylated isoforms of GS and upstream kinases. 40 mg of frozen muscle was cut into 
small pieces and submerged in 600 μl of protein extraction buffer, before homogenising 
using a Qiagen TissueLyser (2 × 30 seconds at 30000 Hz). The samples were then rotated 
end over end for 1 h at 4°C and protein concentration was then determined as above.
Total glycogen synthase expression
Whole muscle protein homogenates were separated using 8% acrylamide gels and 
transferred onto nitrocellulose membranes (Amersham). Total GS expression was measured 
using a rabbit monoclonal antibody to the C-terminus of human GS (Clone EP817Y; 
Epitomics; 1: 10000) and membranes were co-blotted with a mouse monoclonal antibody to 
human desmin (Clone D33, Dako; 1: 50000). Secondary antibodies were HRP-conjugated 
goat antibodies (either anti-rabbit or anti-mouse; BioRad; 1:5000). All antibodies were 
incubated for 1 hour at room temperature. Chemiluminescence was measured with the ECL-
prime kit (Amersham) and Amersham Hyperfilm ECL (GE Healthcare). Assay linearity was 
confirmed with pilot experiments via loading of increasing amounts of protein per lane 
(results not shown). Films were digitised using a Stylus Photo RX640 printer and scanner 
(Epson, Hemel Hempstead, UK) alongside a 21-step transmission step wedge (Stouffer 
Graphic Arts, Mishawaka, USA). The mean grey intensity values from equal rectangular 
areas of each region of the step wedge were quantified in ImageJ (NIH, Bethesda, USA). 
Total GS expression was calculated as a ratio to desmin expression to control for loading.
Phosphorylated GS isoform expression
Muscle protein samples were separated using 8% self cast acrylamide gels and then 
transferred using a semi-dry technique (Amersham TE77) onto a PVDF membrane 
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(Millipore). Sheep polyclonal primary antibodies were those used previously against 
phosphorylation epitopes of sites 1b (2μg/ml), 2+2a (4μg/ml) and 3a+3b (1μg/ml) of GS [35, 
38]. Appropriate HRP-conjugated secondary antibodies were used (Dako; 1:5000). All 
antibodies were incubated for 1 hour at room temperature. Chemiluminesence was measured 
using Luminata Forte HRP chemiluminescent subrstrate (Millipore). After quantification 
using ImageLab software (Biorad), membranes were stripped of antibodies and then re-
incubated with a total GS antibody as previously described. Results are presented as a ratio 
of the phosphorylated enzyme to total GS expression.
GLUT4, GSK3β and AMPK phosphorylation and expression
Using the same technique as for phosphorylated isoforms of GS, total GLUT4 (Pierce; 
1:1000), total GSK3β D transduction Laboratories; 1:500), phosphorylated GSK3β (Cell 
Signalling; 1:1000) and AMPK (α1; 1:5000, α2; 1:15000 and β1; 1:1000, as described by 
Woods et al. [39], β2:1:3000, as described by Durante et al. [40] and pAMPK Thr172; 
1:1000 from Cell Signalling) protein expression levels were measured in whole muscle 
homogenates. Antibodies directed against the AMPK γ1 and γ3 subunits did not detect the 
equine protein. All primary antibodies were diluted in 2% skimmed milk and incubated 
overnight at 4°C and all secondary antibodies were incubated for 45 minutes at room 
temperature. Appropriate HRP-conjugated secondary antibodies were used (Jackson IR; 
0.16μg/ml for pGSK3β. Dako; 1:5000 for all others). GLUT4 and total GSK3β expression 
were quantified in muscle protein samples using α-actin (Sigma; 1:8000) as a loading 
control. Phosphorylated GSK3β was expressed as a ratio to total GSK3β expression. AMPK 
expression was calculated and normalised according to a standard curve derived from 
protein homogenates of known quantities as is custom for this assay [41]. 
Chemiluminesence was measured using Luminata Forte HRP chemiluminescent substrate 
(Millipore) and quantified using ImageLab software (BioRad).
GS baculovirus cloning and expression
Full-length amplicons of R309 wild-type and H309 mutant GYS1 cDNAs, obtained from 
homozygous wild-type and homozygous mutant muscle RNA respectively, were cloned into 
the PH promoter of the pFastBac dual vector (Invitrogen) between the BamH1 and Xba1 
cloning sites. Subsequently, a full-length amplicon of equine glycogenin (GYG1) cDNA was 
subcloned into the p10 promoter of both the wild-type R309 GS*pFastBac and the H309 
mutant Gs*pFastbacs between the Nhe1 and Xho1 cloning sites, allowing co-expression of 
active equine GS with equine glycogenin in Spodoptera frugiperda Sf9 insect cells. Each of 
the cloned insert sequences in each vector was verified with Sanger sequencing. Western 
blot of harvested insect cells from each of 3 different clones of mutant and wild type vectors 
was then used to confirm the expression of wild-type GS and R309H GS together with 
glycogenin. Large culture volumes of these cells (1 litre) were grown and cell pellets 
harvested by Kinnakeet Biotechnology, USA.
Purification of recombinant horse glycogen synthase
The insect cell pellets were resuspended and lysed in 50 ml of extraction buffer containing 
50 mM Tris-HCl, pH 7.8, 300 mM NaCl, 0.1% Triton X-100, 2 mM EDTA, 1 mM 
benzamidine, 0.5 mM phenylmethanesulfonyl fluoride (PMSF), 10 mM β-mercaptoethanol 
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(BME). The crude cell extracts were centrifuged at 35,000 rpm in a Beckman Ti-45 rotor for 
30 minutes at 4°C and the supernatants were collected. Ethanol (kept at −80°C prior to use) 
was slowly added to the clarified cell lysates, under constant stirring, to a final concentration 
of 30%. This process was done in an ice/salt broth so that the temperature stayed between −1 
and −5° C, ensuring complete precipitation of the endogenous insect cell glycogen (no 
additional glycogen was added). The suspensions were then centrifuged at 9000g for 60 min 
at −3°C. The supernatant was discarded and the glycogen pellets were resuspended in 100 
ml of loading buffer containing 50 mM Tris-HCl, 300 mM NaCl, 1 mM benzamidine, 0.5 
mM PMSF and 2 mM BME. The resuspended pellets were then loaded onto a 
Concanavalin-A (Sigma) column. After washing the column with 20 column volumes of 
loading buffer, the protein was gradient eluted with glucose (0-400 mM). The fractions that 
had GS activity (in the presence of 10 mM G6P) were pooled and then dialysed extensively 
against a buffer containing 50 mM Tris-HCl, 300 mM NaCl and 2 mM BME to remove the 
free glucose. The protein was then concentrated and mixed with glycerol to a final 
concentration of 35% and stored at −20° C for long term usage [42].
Specific activity and activity ratio measurement
GS activity was measured in the recombinant enzymes by the method of Thomas et al. 
which quantifies the amount of 14C-glucose transferred from 14C-labelled UDP-glucose to 
glycogen over a period of 15 min at 30°C [43]. Standard reaction conditions used 4.44mM 
UDP-glucose and 6.67 mg/ml of glycogen. Prior to use, rabbit liver glycogen type-III was 
deionised by passing it through TMD-8 hydrogen and hydroxide form-mixed bed exchanger 
resins. Activity was measured both in the presence or absence of 10 mM G6P and before 
and after treatment with 50μg/ml recombinant protein phosphatase 1 (PP1) (gamma) (gift of 
Dr. Anna DePaoli-Roach, Indiana University), the latter in comparison with similarly treated 
recombinant WT and mutant (S7A) human GS (description of S7A mutant given in 
supplementary methods). In order to dephosphorylate phosphorylated serine, threonine and 
tyrosine residues, 50 μg of different GS samples were incubated with 50 μg of PP1 gamma 
catalytic subunit 1, at 30°C for 30 minutes. The reaction mix also contained 0.2mM MnCl2 
which is essential for protein phosphatase 1 activity. After 30 minutes, GS reaction mix was 
added (containing 4.44mM UDP-glucose, 6.67 mg/ml of glycogen, C14 UDP-glucose, 1mM 
1,4-dithiothreitol (DTT) and 1mM EDTA (final concentrations)). The EDTA present in the 
GS reaction mix will terminate the phosphatase reaction. The activity ratio is the ratio of the 
activity in the absence of G6P to the activity in the presence of 10 mM or 7.2mM G6P 
(muscle or insect extracts respectively). Protein concentration was measured by Bradford's 
method, using bovine serum albumin as a standard.
Enzyme kinetics for UDP-Glucose and Glucose-6-Phosphate
For the UDP-glucose titrations, 7 different concentrations of UDPG (0.1 mM to 15 mM for 
the wild type (WT) enzyme and 0.05 mM to 6 mM for the mutant R309H enzyme) were 
used, keeping the glycogen concentration constant at 6.67 mg/ml either in the presence or 
absence of 10 mM G6P. Eight different concentrations of G6P (0.1mM to 20mM for the WT 
enzyme and 0.05mM to 10mM for the mutant R309H enzyme) were used for the G6P 
titrations under standard reaction conditions.
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Kinetic data analysis
The enzyme kinetic data were analyzed using SigmaPlot (v12.3). The activation curves for 
G6P were fitted to the 4 parameter logistic curve and the S0.5 values were obtained from 
these fits. The substrate saturation curves were fitted to the standard Michaelis-Menten 
equation v=Vmax*[S]/(Km+[S]), where v is the reaction rate, [S] is the substrate 
concentration, Vmax is the maximum rate achieved by the system and Km is the substrate 
concentration at half maximum velocity. The Vmax and Km values were obtained from these 
fits and the results represent the mean of 3 separate experiments.
Insect protein site 3a phosphorylation
100ng samples of different GS proteins (as used for kinetic studies) were separated by 10% 
SDS-PAGE and transferred onto a 0.45-μm nitrocellulose membrane (Bio-Rad) at 30 V, 
overnight. After transfer, the membranes were blocked in 5% nonfat milk powder in 1X 
Tris-buffered saline (TBS) containing 0.1% Tween 20. The membrane was then incubated 
overnight at 4° C with phospho 3a (Ser641) specific rabbit GS primary antibody obtained 
from Cell Signaling (3891). The membranes were then washed and subsequently incubated 
with horseradish peroxidase-conjugated secondary antibodies (Cell Signaling, 7074) for 5 h 
at room temperature. Detection was performed by enhanced chemiluminescence using 
Pierce ECL western blot substrate purchased from Thermo Scientific. After detection, the 
membranes were treated with stripping buffer containing 62.5 mM Tris-HCl, pH 6.8, 2% 
sodium dodecyl sulfate, 0.7% β-mercaptoethanol to remove the phospho 3a primary and 
secondary antibodies. After stripping, the same membranes were incubated overnight at 4° C 
with rabbit GS specific primary antibodies (Cell Signaling, 3886). The membranes were 
then washed, treated with secondary antibodies and developed as described above. In all 
cases, prior to use, the primary and secondary antibodies were diluted 1:2000 and 1:4000, 
respectively. Densitometric analysis of the immunoblots was performed using Quantity One 
software package.
Homology modelling
X-ray crystal structures of S. cerevisiae Gsy2p in the basal state (PDB code 3NAZ; 3 Å 
resolution) and G6P bound state (PDB code 3NB0; 2.41 Å resolution) provided the 
templates for homology modelling of equine GS. The full-length sequence of equine GS was 
retrieved from Genbank (accession ACB14276) and sequence aligned with S. cerevisiae 
Gsy2p using Clustal Omega [44]. MODELLER software [45] was used to generate 50 
models of both the basal and bound tetrameric forms of equine GS. In both cases the internal 
scoring function of MODELLER was used to select 10 models that were visually inspected 
and submitted to the VADAR webserver [46] for assessment of stereochemical soundness in 
order to select a single best model. The R309H mutation was introduced into both models 
using SwissPDBViewer [47]. Model figures were generated using PyMOL (DeLano 
Scientific, San Carlos, CA, U.S.A.).
Statistical analysis
Data calculations and statistical analysis were performed using GraphPad Prism (Version 
6.0). Due to the small sample size for the homozygous mutant group, non-parametric 
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statistics were performed and statistical significance was assessed via a Kruskal-Wallis test 
and Dunn's post-hoc multiple comparison test. Results were considered statistically 
significant when P<0.05. Pearson's correlation was used to examine association between 
continuous variables.
Results
Breed and signalment data
There were no significant differences in age, sex or breed of the 3 genotyped groups used for 
this study (Table S1).
Muscle glycogen content, GS activity and total GS expression
Heterozygote (RH) and homozygote (HH) mutant horses had significantly higher glycogen 
content in skeletal muscle than control (RR) horses (Figure 1A), despite there being no 
difference in total muscle GS expression between each of the genotyped groups (p=0.98) 
(Figure 1B). The higher glycogen content of mutant horse muscle was accompanied by 
higher GS activity in muscle samples from homozygotes (HH) compared to samples from 
heterozygotes and between homozygotes (HH) and WT controls (RR) in the presence 
(Figure 1C, %FV, p=0.03) and the absence of G6P (Figure 1D, %I-form, p=0.04) but there 
was no difference in maximal GS enzyme activity between genotypes (p=0.20, data not 
shown).
Phosphorylation of GS
PSSM1-homozygote muscle samples had greater phosphorylation at site 2+2a than WT 
samples (Figure 2B; p=0.009). There were no detectable differences in levels of GS 
phosphorylation at the other target sites (1b and 3a+3b) between the genotypes (Figure 2A 
and 2C).
GS activity is dependent on its phosphorylation; in particular, phosphorylation of sites 3a, 3b 
and 2+2a and is highly dependent on glycogen content via negative feedback [35]. Due to 
the significant increase in phosphorylation at sites 2+2a, correlation coefficients were 
calculated between site 2+2a phosphorylation and glycogen content and GS activity. Muscle 
glycogen content was significantly, but weakly correlated with the degree of GS site 2+2a 
GS phosphorylation (R2=0.23, p=0.04); there was no significant association between 
phosphorylation at site 2+2a and GS activity (data from whole cohort; p=0.54).
GLUT4, GSK3β and AMPK expression
There was no difference in expression of GLUT4 (p=0.42), total GSK3β (p=0.49) or in the 
ratio of phosphorylated GSK3β (Ser9) to total GSK3β (p=0.43) between different 
genotypes (data not shown). However, there was significantly higher expression of 
AMPKα1 protein in the PSSM1-homozygote samples compared to WT controls (Figure 3A; 
p=0.04) and a trend towards elevated phosphorylation of AMPK (pAMPK) in PSSM1-
homozygote muscle samples compared to WT and heterozygotes (Figure 3E), although this 
did not reach significance (p=0.13). There was a significant and strong association between 
AMPKα1 expression and pAMPK (Figure 3F; R2=0.66, p<0.0001). There was also 
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significantly lower AMPKβ1 expression in PSSM1-homozygote samples compared to 
heterozygotes (Figure 3C; p=0.03) but not compared to WT controls.
Kinetics of expressed and purified GS
WT and mutant equine GS were expressed in insect cells and the purified enzymes were 
used to compare kinetic parameters, including dependence on G6P concentration, the Km for 
UDPG and Vmax in the presence and absence of G6P, the Vmax/Km ratios with and without 
G6P, and the S0.5 for G6P in the presence of 4.4 mM UDPG.
The G6P titration curves for the WT and the R309H mutant enzymes show that the activity 
of both enzymes increased with increasing G6P concentrations and that the mutant enzyme 
is nearly maximally activated at G6P concentrations that barely activate the WT enzyme 
(Figure 4A). Specifically, G6P activated both the WT and mutant enzymes with an S0.5 
value of around 3.0 mM and 0.24 mM respectively (Table 1).
GS activity measurements performed at varying UDPG concentrations (Figure 4B), in the 
absence and presence of maximal (10 mM) G6P, revealed that the mutant enzyme had a 
much lower Km for UDPG (0.48 and 0.18 mM, with and without G6P, respectively) than the 
WT enzyme (2.4 and 1.6 mM, with and without G6P, respectively (Table 1). The Vmax/Km 
ratios with and without G6P were also much higher for the mutant when compared to the 
WT GS (Table 1).
The R309H mutant enzyme shows an approximately 20 fold higher activity ratio than the 
WT enzyme (Table 2), due largely to the mutant enzyme's marked activation in the absence 
of G6P. The low activity ratio seen in the WT equine GS enzyme (0.02) is similar to that 
detectable in baculovirus-generated human GS [48]. Despite both the equine WT and mutant 
insect-derived enzymes’ phosphorylation (at site 3a) (Figure 5A), the mutant equine enzyme 
had a high activity ratio, similar to that of the S7A mutant human GS, (which cannot be 
phosphorylated) (Figure 5B). Phosphatase treatment induced a marked increase in the 
activity ratio of both the WT equine and human GS enzymes from minimal baseline ratios as 
expected; in contrast, there was little change in the activity ratio of WT equine enzyme 
which behaved similarly to the S7A mutant human enzyme (Figure 5B).
Glycogen synthase homology modelling
The residues resolved in the G6P-bound crystal structure of yeast Gsy2p and the 
corresponding region of equine GS share 55% sequence overall identity (Figure 6). 
Conserved residues include the binding determinants of G6P and maltodextrin. In addition, 
the R309 residue and the 5 surrounding residues of equine GS are conserved as R298 in 
yeast Gsy2p (Figure 6). Therefore Gsy2p structures with and without G6P bound, provided 
suitable structural templates for homology modelling of equine GS as a homotetramer with 
basal and active conformations, respectively (Figure 7A and B).
As a first step in understanding the structural effects of the R309H mutation, the 
environment around R309 was inspected in the WT GS models. In both basal and active GS 
models, R309 is distal from the G6P and maltodextrin binding sites (Figure 7A and B) and is 
therefore not predicted to form a direct binding contact for either substrate. Nevertheless, 
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R309 is located on the C-terminal end of an α-helix that contains 4 residues (H291, Q294, 
H297, K301) that are G6P binding determinants. In addition, R309 is positioned adjacent to 
a pair of α-helices that use a coiled-coil interaction to form the major interface between 
subunits of the tetramer. Indeed, conformational transition between basal and active states 
involves translation and rotation around this central tetrameric interface [26] (Figure 7A and 
B).
R309 in the GS models and the corresponding R298 residue in the yeast Gsy2p structures 
have similar interactions (Figure 7C-H). Gsy2p R298 forms a salt bridge with the side 
chains of D295 in the basal state (Figure 7G). This interaction is lost in the active state 
(Figure 7H) and, whereas R298 forms no new interactions, its former interaction partner, 
D295, instead forms a salt bridge with residue R376. R376 is located on the adjacent α-helix 
that forms the aforementioned coiled-coil configuration of the enzyme subunit interface. A 
similar state-dependent switch in salt bridges is found with equine WT GS. R309 engages in 
a salt bridge with E306 and, as with Gsy2P, this interaction is lost in the active state where 
E306 is instead available to form a salt bridge with K387.
The R309H mutation was introduced into GS models and the predicted outcome was the 
elimination of the salt bridge interaction with E306 in the basal-state conformation (Figure 
7E). Release of E306 from an interaction with the 309 position may instead allow it to 
interact with the adjacent K387 even in mutant enzyme's basal state.
Discussion
The inherited skeletal muscle disorder known as PSSM1, caused by a missense mutation in 
the equine GYS1 gene [8] is histopathologically characterised by increased amylopectate 
and glycogen in skeletal muscle fibres [9, 10]. Here, we employed a multi-disciplinary 
approach in order to determine if the basis for the previously-identified, increased GS 
activity in PSSM1-affected muscle [8] is associated with altered GS enzyme expression, 
dysregulation of GS activity, or a GS protein conformational change with possible 
constitutive activation. Our results reveal that the R309H mutation, responsible for this 
highly prevalent equine polyglucosan myopathy, present in over 20 breeds worldwide 
[12-15], is caused by constitutive activation; furthermore, we propose the probable 
mechanism, based on modelling analyses of the mutant GS structure.
Similar to previous results in Quarter Horses, (a PSSM1-affected light horse breed) [49], we 
have shown that mutant draught horses with the same mutation have increased muscle 
glycogen storage despite normal GLUT4 transporter expression. Homozygous mutant 
muscle had increased GS activity compared to homozygous WT muscle, even though there 
was no difference in total GS expression between genotypes. GS in skeletal muscle from 
homozygous mutant horses had increased G6P-independent activity (%I-form), consistent 
with data from McCue et al., who detected higher GS activity, irrespective of G6P 
concentration, in PSSM1-affected Quarter Horses [8]. Despite the differences between 
PSSM1-homozygotes and PSSM1-heterozygotes in terms of muscle GS activity, there was 
no difference between these groups in the glycogen content of their muscle, but the reason is 
unclear. As GS activity is inversely correlated with the extent of site 2+2a GS 
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phosphorylation in healthy muscle [35, 38, 50], the higher enzyme activity in mutant horses 
cannot be explained by inappropriate (i.e. reduced) GS phosphorylation, since muscle from 
affected horses actually had significantly more GS phosphorylation at site 2+2a, (and no 
difference in phosphorylation at other evaluated sites) when compared with controls. As 
expected in healthy muscle [36], PSSM1-affected horses had increased phosphorylation at 
site 2+2a in the presence of elevated muscle glycogen, most likely reflecting a normal 
physiological attempt to reduce enzyme activity [35, 50-52]; indeed, the high GS activity in 
mutant horses occurs despite the phosphorylation and increased expression of AMPK, the 
principal upstream kinase for phosphorylation at site 2. Therefore, phosphorylation of the 
mutant enzyme at site 2+2a does not correspondingly lower its activity.
The increased activity detectable in PSSM1-horse muscle most likely results from a 
constitutive change in the mutant enzyme's function, similar to that of a yeast mutant that 
also fails to respond appropriately to phosphorylation [8, 20] or to increased glycogen 
content [53]. In order to test this hypothesis, enzyme kinetic studies were performed using 
purified protein extracts derived from allele-specific GS, expressed in insect cells. These 
analyses revealed that the mutant enzyme behaves as if it is nearly fully active even in the 
absence of its allosteric activator, G6P as is shown by the significantly lower Km and 
increased Vmax in the absence of G6P. Further, the R309H enzyme had significantly lower 
Km for UDPG even in the absence of G6P and the Vmax/Km value for the mutant enzyme in 
the absence of G6P was increased over 60 fold, when compared to the WT enzyme. In 
contrast, the activity ratio of the WT equine enzyme was similar to that of human GS 
purified in a similar manner [48]. Further, there was no detectable difference in the extent of 
3a phosphorylation between the WT and mutant recombinant enzymes, but despite this, the 
equine recombinant enzyme behaved similarly to that of a mutant human enzyme that 
cannot be phosphorylated, both with and without pre-treatment with protein phosphatase 1. 
Our data therefore confirm that the R309H mutation associated with PSSM1 is a true, gain 
of function mutation.
The phosphorylation sites of muscle GS are located on the N- and C- termini of the enzyme 
[54, 55]. We were unable to use homology modelling to investigate these sites as there are 
no corresponding regions resolved in the yeast Gsy2p structures. Nevertheless, the region 
around R309 was modelled (Figure 7) and, although not predicted to form a binding contact 
for G6P or maltodextrin (Figure 7A and B), this residue is positioned at a pivotal position 
near the tetrameric interface of the enzyme and is located on an α-helix that harbours 4 G6P 
binding residues. Therefore, a structural perturbation at the 309 position could influence the 
position of the conformational equilibrium making it easier to adopt the active conformation. 
Modelling indicates that in the enzyme's basal state, R309 normally engages in a salt bridge 
with E306 whereas in the active state, E306 forms an alternative salt bridge with K387 
(Figure 7C and D). These salt bridge interactions might be important for stabilising the 
conformation of their respective functional states. We therefore propose that the R309H 
mutation, which is predicted to eliminate the basal-state salt bridge (Figure 7E), likely shifts 
the conformational equilibrium of the enzyme to the active state and reduces its tendency to 
adopt an inhibited state (Figure 7F). Interestingly, the residue adjacent to R309 is conserved 
as a glycine in both equine GS (G310) and in yeast Gsy2p (G299) where its mutation results 
in increased Gsy2p activity [20]. This glycine is located at a turn at the C-terminal end of the 
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helix containing R298 (equivalent to equine R309) and G6P binding contacts. It is therefore 
positioned to function as a typical glycine-hinge residue and the reported mutation-
associated change in enzyme activity [15], provides further evidence that structural 
deviations in this region produce constitutive activation.
In summary, our work provides further evidence that the PSSM1-associated R309H GYS1 
mutation results in increased glycogen content and GS activity in skeletal muscle. We show 
that this elevated activity results in an altered sensitivity to G6P, increased affinity for UDPG 
and occurs despite hyperphosphorylation at site 2+2a and increased expression of AMPK. 
Further, for the first time, we suggest through predictive modelling a potential mechanism 
by which this occurs. Additional work is needed to explain all the phenotypic features of this 
equine disorder, including the intermittent rhabdomyolysis and gait abnormalities seen in 
some affected horses. ATP depletion is a common cause of rhabdomyolysis in humans and 
therefore further work investigating metabolic responses in affected horses might help 
explain some aspects of the clinical phenotypes in this disorder. However, our results suggest 
that therapeutic modification of AMPK activity might be ineffective in mutant animals, as 
increased GS phosphorylation does not reduce the mutant enzyme's hyperactivity; instead, 
efforts aimed at direct enzyme inhibition might be more effective. Finally, dysregulation of 
GS or other related enzymes should be considered in humans and animals with glycogen 
storage diseases of unknown origin, particularly when a dominant mode of inheritance is 
identified; indeed, this common equine disease represents a large animal model for 
evaluation of treatments aimed at reducing polyglucosan formation in skeletal muscle [33], a 
feature of a number of important, but comparatively rare, human myopathic disorders.
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Highlights
• PSSM1-associated GYS1 mutation causes constitutive enzyme 
activation.
• A conformational mechanism for this activation is proposed via in 
silico modeling.
• The mutant enzyme is highly active in the absence of its allosteric 
activator.
• The mutant enzyme does not respond appropriately to phosphorylation.
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Figure 1. 
A) Glycogen content of wet weight muscle samples from WT (RR)(n=7), PSSM1-
heterozygotes (RH)(n=8) and PSSM1-homozygotes (HH)(n=4) horses (median +/− min/max 
values, box represents interquartile range; RR vs. RH p=0.005, RR vs. HH p= 0.041, 
*p<0.05). B) Total glycogen synthase expression in muscle homogenates from each of the 
genotypes was not significantly different (p=0.98). Glycogen synthase activity shown as C) 
fractional velocity (FV) and D) l-form activity. There was an increase in %FV between 
PSSM1-homozygotes (HH) and WT controls (RR) (p=0.03) and an increase in %I-form 
activity between heterozygotes (RH) and PSSM1-homozygotes (HH) samples (p=0.04) 
(median +/− min/max values, box represents interquartile range, RR (n= 12), RH (n=13), 
HH (n=4) *p<0.05).
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Figure 2. Western blot analysis of GS phosphorylation in skeletal muscle homogenates
There were no significant differences between the genotypes for phosphorylation of A) p1b 
isoform (p=0.48) and C) p3a+3b isoform (p=0.17). There was significantly increased 
phosphorylation at sites p2+2a (B) in PSSM1-homozygotes compared to control horses 
(RR) (p=0.009); (mean +/− SEM, RR (n=12) RH (n=13) HH (n=3) *p<0.05).
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Figure 3. AMPK subunit expression and phosphorylation at Thr 172 from skeletal muscle 
extracts
There was a significant increase in AMPKα1 expression in PSSM1-homozygote samples 
(HH) compared to heterozygotes (RH) and WT controls (RR) (A; p=0.04) and a significant 
decrease in AMPKβ1 expression in the PSSM1-homozygote samples (HH) compared to the 
heterozygotes (C; p=0.03). There were no significant differences in AMPKα2 (p=0.15) or 
AMPKβ2 (p=0.28) expression between different genotypes (B and D). There was a 
significant and strong correlation between AMPKα1 and pAMPK expression (F; R2=0.66, 
p<0.0001). (mean +/− SEM, RR (n=12) RH (n=13) HH (n=3) *p<0.05). Data for A to E is 
normalised to the mean of the WT control samples.
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Figure 4. A) Glucose-6-phosphate and B) UDPG titration (with or without 10mM G6P) curves 
for WT and R309H mutant enzyme
These curves show that the mutant enzyme has much higher enzyme activity at much lower 
concentrations of G6P and reaches its maximal activity at much lower G6P concentrations 
(A). The mutant enzyme also has a higher affinity for UDPG (B). (Mean +/− SEM, n=3 
repeats)
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Figure 5. Phosphorylation (A) and Activity ratio (B) of insect derived WT and mutant (R309H) 
equine and human WT and S7A glycogen synthases
Activity ratio is minimal in both equine and human WT enzymes that are untreated with 
protein phosphatase 1 (PP1), but each WT enzymes’ activity ratio increased when treated 
with the enzyme. In contrast, the equine mutant enzyme has a high ratio both with and 
without treatment with PP1 as also seen with the S7A human mutant GS, despite the equine 
mutant enzyme's phosphorylation. (n=3 replicates for each condition / enzyme; mean +/− 
SD).
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Figure 6. Sequence alignment of equine GS (Genbank accession ACB14276) and yeast Gsy2 
(sequence in PDB ID 3NB0)
Red star: R309 in equine GS and the location of the PSSM1-associated R309H mutation. 
Magenta circles: predicted phosphorylation sites. Blue triangles: binding residues of 
glucose-6-phosphate. Diamonds: binding residues of maltodextrin (yellow: sites 1 and 2; 
green: sites 3 and 4).
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Figure 7. Homology models of equine GS
(A) Basal and (B) active-state equine WT GS model tetramers are shown as ribbons with 
monomers coloured different shades of grey. Residues in space-fill are R309 (red), G6P-
binding contacts (blue) and maltodextrin-binding contacts (yellow: sites 1 and 2; green: sites 
3 and 4). The 309 position and local charged residues are shown as sticks for WT GS [(C) 
basal; (D) active-state] and the PSSM1-associated R309H mutant [(E) basal; (F) active-
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state]. Also shown as sticks are the corresponding residues in the crystal structures of yeast 
Gsy2p [(G) basal; (H) active-state]. Salt bridge interactions are shown as green dashes.
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Table 1
Comparison of kinetics of WT and mutant (R309H) GS enzyme.
Protein Km UDPG 
(mM) (-
G6P)
Km UDPG 
(mM) 
(10mM 
G6P)
Vmax 
UDPG 
(μmol/
min.mg) (-
G6P)
Vmax 
UDPG 
(μmol/
min.mg) 
(10mM 
G6P)
Vmax/Km (-G6P) Vmax/Km (10mM G6P) S0.5 G6P 
(mM) 
(4.4mM 
UDPG)
WT GS 2.4 ±0.2 1.6 ±0.1 0.05 ±0.01 3.1 ±0.1 0.023 ±0.002 2.0 ±0.2 3.0 ±0.4
R309H GS 0.48 ±0.01 0.18 ±0.02 0.72 ±0.06 1.9 ±0.1 1.5 ±0.3 11 ±2 0.24 ±0.03
Values given are the mean ±SEM from 3 separate experiments.
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Table 2
Specific activity of WT and R309H mutant GS in absence and presence of G6P (n=3).
Specific activity –G6P (umol/min.mg) Specific activity 10mM G6P (umol/min.mg) Activity ratio
WT GS 0.04 2.33 0.02
R309H GS 0.36 1.06 0.34
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